重组人干扰素α-2b凝胶联合聚甲酚磺醛溶液治疗宫颈病变人乳头瘤病毒感染患者的疗效

Effect of recombinant human interferon α-2b combined with polycresol sulfonaldehyde solution on treatment of patients with cervical lesions and human papillomavirus infection

目的探讨重组人干扰素α-2b凝胶联合聚甲酚磺醛溶液对宫颈病变人乳头瘤病毒(HPV)感染患者T淋巴细胞亚群及干扰素ε(IFN-ε)、C-反应蛋白(CRP)、白细胞介素-17(IL-17)的影响。方法选取2016年1月-2018年12月金昌市中西医结合医院就诊的宫颈病变HPV感染患者120例为研究对象,并按随机数字表法分为对照组和研究组,每组60例。对照组患者采用聚甲酚磺醛溶液进行宫颈局部治疗,4 d治疗1次,连续3个月;研究组在对照组基础上给予重组人干扰素α-2b凝胶阴道给药治疗,隔天1次, 12次为1疗程,连续治疗3个疗程。治疗后,统计并比较两组的临床疗效、HPV转阴率;分析治疗前后T淋巴细胞亚群及血清IFN-ε、CRP、IL-17水平变化;比较两组患者不良反应发生情况。结果研究组治疗总有效率(93.33%)显著高于对照组治疗总有效率(78.33%),两组比较有统计学意义(χ^(2)=5.551,P=0.018);研究组患者总转阴率(85.00%)显著高于对照组(58.33%),两组比较有统计学意义(χ^(2)=10.506,P<0.05);治疗后两组患者外周血T淋巴细胞CD_(3)^(+)、CD_(4)^(+)、CD_(4)^(+)/CD__(8)^(+)水平均升高,外周血Treg、Th17、CD__(8)^(+)水平均降低,两组比较有显著差异(P<0.05);治疗后研究组患者血清IFN-ε水平高于对照组,CRP、IL-17水平低于对照组(P<0.05);两组不良反应发生情况差异无统计学意义。结论重组人干扰素α-2b凝胶联合聚甲酚磺醛溶液治疗宫颈病变HPV感染可显著增强临床疗效,促进HPV其他型感染转阴,同时可显著调节T淋巴细胞亚群与IFN-ε、CRP、IL-17水平,增强患者免疫功能,抑制机体炎症反应,且安全可靠,值得临床推广应用。

OBJECTIVE To explore the effect of recombinant human interferonα-2 b combined with polycresol sulfonaldehyde solution on T lymphocyte subsets and interferon-ε(IFN-ε),C-reactive protein(CRP)and interleukin-17(IL-17)of the patients with cervical lesions and human papillomavirus(HPV)infection.METHODS A total of patients with cervical lesions and HPV infection who were treated in the Hospital of Traditional Chinese and Western Medicine,Jinchang from Jan 2016 to Dec 2018 were recruited as the study subjects and randomly divided into the control group and the study group,with 60 cases in each group.The control group was treated with polycresol sulfonal solution for local cervical treatment,once every 4 days for 3 consecutive months;the study group was given vaginal administration of recombinant human interferonα-2 b gel on the basis of the control group,once every other day,12 times as a course of treatment,and three consecutive courses of treatment.The clinical curative effect and negative rate of HPV were compared between the two groups,the changes of levels of T lymphocyte subsets,serum IFN-ε,CRP and IL-17 were observed before and after the treatment,and the incidence of adverse reactions was compared between the two groups of patients.RESULTS The total effective rate of treatment of the study group was 93.33%,significantly higher than 78.33%of the control group(χ^(2)=5.551,P=0.018).The total negative rate of the study group was 85.00%,significantly higher than 58.33%of the control group(χ^(2)=10.506,P<0.05).The levels of peripheral blood T lymphocytes CD3+,CD_(4)^(+)and CD_(4)^(+)/CD_(8)^(+)of the two groups of patients were significantly higher after the treatment than before the treatment,the levels of peripheral blood Treg,Th17 and CD_(8)^(+)were lower after than treatment than before the treatment(P<0.05).The serum IFN-εlevel of the study group was significantly higher than that of the control group after the treatment,while the levels of CRP and IL-17 of the study group were significantly lower than those of the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups.CONCLUSION Recombinant human interferonα-2 b combined with cresol sulfonal solution can significantly improve the clinical efficacy in treatment of the patients with cervical lesions and HPV infection,raise the negative rate of other HPV infections,significantly regulate the T lymphocyte subsets and the levels of IFN-ε,CRP,and IL-17,enhance the immune function of the patients and inhibit the body′s inflammatory response,it is safe and worthy to be promoted in the hospital.